Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...
Between 2019 and 2023, the market grew at a CAGR of 9%, driven by the rising health-consciousness of consumers, particularly millennial and Gen-Z parents. As precision nutrition technologies advance, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback